Cas no 65592-96-3 (2-(1H-Imidazol-5-yl)ethanamine)

2-(1H-Imidazol-5-yl)ethanamine is a heterocyclic organic compound featuring an imidazole ring linked to an ethylamine side chain. This structure imparts unique reactivity, making it a valuable intermediate in pharmaceutical and biochemical research. Its imidazole moiety provides coordination sites for metal binding, while the primary amine group enables further functionalization through amide or Schiff base formation. The compound is particularly useful in synthesizing histamine analogs, enzyme inhibitors, and metal-chelating agents. Its stability under physiological conditions and compatibility with aqueous and organic solvents enhance its versatility in synthetic applications. Researchers favor it for its well-defined reactivity profile and potential in designing bioactive molecules.
2-(1H-Imidazol-5-yl)ethanamine structure
65592-96-3 structure
Product Name:2-(1H-Imidazol-5-yl)ethanamine
CAS No:65592-96-3
MF:C5H10N3
MW:112.153000354767
CID:874240
PubChem ID:25201573
Update Time:2025-06-14

2-(1H-Imidazol-5-yl)ethanamine Chemical and Physical Properties

Names and Identifiers

    • 2-(1H-Imidazol-5-yl)ethanamine
    • [2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
    • 2-(3H-Imidazol-4-yl)-ethylamine
    • 2,6-DICHLOROIODOBENZENE
    • 2-(1H-Imidazol-4-yl)ethanamine
    • Histamine, >=97.0%
    • NCGC00015513-03
    • HISTAMINE [HSDB]
    • 2-(1H-Imidazol-4-yl)ethanamine #
    • s10979
    • DTXSID4023125
    • 748 - Fish based sample
    • GTPL1247
    • BP-11484
    • 1H-Imidazole-5-ethanamine
    • beta-aminothethylglyoxaline
    • KBio3_000853
    • Eramin
    • peremin
    • Spectrum5_000796
    • HISTAMINE (MART.)
    • 2-imidazol-5-ylethylamine
    • Histamine [USAN]
    • KBio2_003025
    • imido-
    • Opera_ID_1772
    • BCBcMAP01_000250
    • NCGC00093371-04
    • EN300-78991
    • Histamine Dihydrochloride (Salt/Mix)
    • beta-Aminoethylglyoxaline
    • DivK1c_000308
    • NCGC00093371-05
    • J-505349
    • MLS000069447
    • BRD-K01674964-300-06-3
    • 3h-histamine
    • 5-Imidazoleethylamine
    • HISTAMINE FREE BASE CRYSTALLINE
    • Histamine, Free Base
    • Lopac0_000595
    • SY041787
    • 1avn
    • CHEBI:18295
    • BDBM7966
    • Tox21_110166_1
    • KBioGR_000457
    • 1qft
    • 2-(3H-imidazol-4-yl)ethylamine
    • BRD-K01674964-316-01-0
    • HMS1792G19
    • Histamine, analytical standard
    • DB05381
    • BRD-K01674964-300-08-9
    • .beta.-Imidazolyl-4-ethylamine
    • Istamina
    • BDBM50121205
    • L-Histamin base
    • 2-(1H-imidazol-5-yl)ethan-1-amine
    • KBio2_001325
    • ethylamine, 2-(4'-imidazolyl)-
    • Ergamine
    • AKOS009158347
    • beta-Aminoethylimidazole
    • FS-5386
    • NCGC00015513-10
    • KBioSS_001325
    • beta-Imidazolyl-4-ethylamine
    • Ceplene
    • HMS3885M14
    • CCRIS 6535
    • UNII-820484N8I3
    • Histamine (DCF)
    • HISTAMINE [MI]
    • SCHEMBL2279
    • STK346752
    • NCGC00015513-11
    • F10913
    • AB00053481_21
    • AB00053481_20
    • KBio2_006461
    • NCGC00015513-25
    • NINDS_000308
    • ALBB-005968
    • HMS1362G19
    • 2-(1H-IMIDAZOL-4-YL)-1-ETHANAMINE
    • Tox21_110166
    • NCGC00015513-02
    • GTPL1204
    • CHEMBL90
    • EINECS 200-100-6
    • Spectrum2_000665
    • Bio1_000487
    • SMP1_000151
    • Racemic histamine
    • KBio2_005593
    • NCGC00015513-09
    • IDI1_000308
    • Histaminum (TN)
    • Bio1_001465
    • NSC 33792
    • CS-0368357
    • .beta.-Aminoethylimidazole
    • KBioGR_001580
    • NCGC00015513-08
    • Imidazole, 4-(2-aminoethyl)-
    • .beta.-Aminoethylglyoxaline
    • F411C768-A159-4FC0-A195-291A08BB03AA
    • 65592-96-3
    • Free histamine
    • [3H]histamine
    • AC-13185
    • D08040
    • HMS3403G19
    • 2-(4-Imidazolyl)ethanamine
    • KBio1_000308
    • CCG-204684
    • Bio1_000976
    • b-Imidazolyl-4-ethylamine
    • [2-(1H-imidazol-4-yl)ethyl]amine
    • Imidazole-4-ethylamine
    • 2-(3H-imidazol-4-yl)ethanamine
    • SDCCGSBI-0050577.P005
    • Ergotidine
    • 2-(1H-Imidazol-5-yl)ethylamine
    • DTXCID103125
    • CAS-51-45-6
    • 2-imidazol-4-yl-Ethylamine
    • ALEROFF
    • C00388
    • HMS1990G19
    • L-histamine
    • HSDB 3338
    • Bio2_000389
    • Bio2_000869
    • NCGC00015513-06
    • HISTAMINE [VANDF]
    • L000292
    • bmse000744
    • BSPBio_001117
    • KBioSS_000457
    • NS00004684
    • 2-(1H-Imidazol-4-yl)ethylamine
    • Histamine, Free Base - CAS 51-45-6
    • MFCD00005210
    • 4-(2-Aminoethyl)-1H-imidazole
    • Histamine, Vetec(TM) reagent grade, >=97%
    • 2-(4-Imidazolyl)ethylamine
    • BRD-K01674964-300-07-1
    • SBI-0050577.P004
    • 1H-Imidazole-4-ethanamine
    • 51-45-6
    • Theramine
    • SMR000059091
    • NCGC00093371-02
    • F2173-0575
    • MFCD00128939
    • histamine
    • NCGC00093371-03
    • (1H-imidazol-4-yl)ethylamine
    • CS-4697
    • KBio2_003893
    • KBio3_000854
    • HISTAMINE [WHO-DD]
    • HY-B1204
    • Spectrum4_000960
    • BBL004932
    • Q61233
    • s3968
    • NCGC00015513-01
    • 4-Imidazoleethylamine
    • imidazole, 4(5)-(2-aminoethyl)-
    • IDI1_002144
    • Spectrum_000845
    • AKOS000274386
    • NSC-33792
    • 2-(1H-imidazol-4-yl)ethan-1-amine
    • HMS3743G03
    • BSPBio_002124
    • SPBio_000729
    • WLN: T5M CNJ D2Z
    • KBio2_000457
    • 2-(1H-Imidazol-4-yl)-ethylamine
    • SDCCGMLS-0066601.P001
    • NCGC00015513-04
    • Istamina [Italian]
    • NCGC00015513-07
    • NCGC00015513-05
    • Ethylamine, 2-imidazol-4-yl-
    • Histaminum
    • Histamine Base
    • Lopac-H-7250
    • 820484N8I3
    • 117932-92-0
    • Spectrum3_000452
    • NSC33792
    • HISTAMINE [MART.]
    • BRD-K01674964-001-19-0
    • 2-Imidazol-4-ylethylamine
    • KBio3_001344
    • Histamine, base, >=97.0% (NT)
    • Histamine, EuropePharmacopoeia (EP) Reference Standard
    • 4-(2-Aminoethyl)imidazole
    • Inchi： 1S/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)/p+1
    • InChI Key： NTYJJOPFIAHURM-UHFFFAOYSA-O
    • SMILES： [NH3+]CCC1=CN=CN1

Computed Properties

  • Exact Mass: 111.08000
  • Monoisotopic Mass: 112.087472332g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 1
  • Heavy Atom Count: 8
  • Rotatable Bond Count: 2
  • Complexity: 64.7
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: -0.7
  • Topological Polar Surface Area: 56.3?2

Experimental Properties

  • Density: 1.1±0.1 g/cm3
  • Boiling Point: 380.3±0.0 °C at 760 mmHg
  • Flash Point: 180.3±8.1 °C
  • PSA: 54.70000
  • LogP: 0.61120
  • Vapor Pressure: 0.0±0.8 mmHg at 25°C

2-(1H-Imidazol-5-yl)ethanamine Security Information

2-(1H-Imidazol-5-yl)ethanamine Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Alichem
A069004288-1g
2-(1H-Imidazol-5-yl)ethanamine
 65592-96-3 95%
1g
 $400.00 2023-09-01
Chemenu
CM186811-1g
2-(1H-Imidazol-5-yl)ethanamine
 65592-96-3 95%
1g
 $408 2021-08-05
Apollo Scientific
OR310729-1g
[2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
 65592-96-3
1g
 ￡358.00 2023-09-02
Chemenu
CM186811-5g
2-(1H-Imidazol-5-yl)ethanamine
 65592-96-3 95%+
5g
 $*** 2023-05-29
A2B Chem LLC
AB58824-1mg
[2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
 65592-96-3 >95%
1mg
 $201.00 2024-04-19
A2B Chem LLC
AB58824-5mg
[2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
 65592-96-3 >95%
5mg
 $214.00 2024-04-19
A2B Chem LLC
AB58824-10mg
[2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
 65592-96-3 >95%
10mg
 $240.00 2024-04-19
A2B Chem LLC
AB58824-500mg
[2-(1H-Imidazol-5-yl)ethyl]amine dihydrochloride
 65592-96-3 >95%
500mg
 $390.00 2024-04-19
SHANG HAI HAO HONG Biomedical Technology Co., Ltd.
1439027-1g
2-(1H-Imidazol-4-yl)ethanamine
 65592-96-3 95+%
1g
 ￥3672.00 2024-05-05

2-(1H-Imidazol-5-yl)ethanamine Related Literature

Related Categories

Additional information on 2-(1H-Imidazol-5-yl)ethanamine

Recent Advances in the Study of 2-(1H-Imidazol-5-yl)ethanamine (CAS: 65592-96-3) and Its Applications in Chemical Biology and Medicine

The compound 2-(1H-Imidazol-5-yl)ethanamine (CAS: 65592-96-3) has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This molecule, characterized by its imidazole ring and ethylamine side chain, serves as a critical building block in the synthesis of various bioactive compounds. Recent studies have explored its role in modulating enzymatic activity, receptor binding, and as a precursor in the development of novel therapeutics.

One of the most notable advancements in this area is the identification of 2-(1H-Imidazol-5-yl)ethanamine as a key intermediate in the synthesis of histamine receptor ligands. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in enhancing the binding affinity of histamine H3 receptor antagonists, which are promising candidates for treating neurological disorders such as Alzheimer's disease and schizophrenia. The study utilized advanced computational modeling and in vitro assays to validate the compound's potential, highlighting its structural flexibility and pharmacophoric properties.

In addition to its role in receptor modulation, 2-(1H-Imidazol-5-yl)ethanamine has been investigated for its antimicrobial properties. A recent preprint on bioRxiv reported its incorporation into novel peptidomimetics that exhibit potent activity against multidrug-resistant bacterial strains. The researchers employed a combination of solid-phase peptide synthesis and high-throughput screening to optimize the compound's efficacy, revealing its potential as a scaffold for next-generation antibiotics.

Another groundbreaking application of this compound lies in the field of cancer research. A 2024 study in Nature Chemical Biology detailed its use in the development of small-molecule inhibitors targeting histone demethylases, enzymes implicated in epigenetic regulation and oncogenesis. The study showcased the compound's ability to selectively inhibit specific demethylase isoforms, offering a new avenue for targeted cancer therapy. These findings underscore the compound's versatility and its growing importance in drug discovery pipelines.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic and safety profiles of derivatives based on 2-(1H-Imidazol-5-yl)ethanamine. Future research directions may include structural modifications to improve bioavailability and reduce off-target effects, as well as large-scale clinical trials to validate its therapeutic potential. Overall, the continued exploration of this compound holds great promise for advancing both basic science and translational medicine.

65592-96-3 (2-(1H-Imidazol-5-yl)ethanamine) Related Products

Recommended suppliers
煙臺(tái)朗裕新材料科技有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Jinta Yudi Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinta Yudi Pharmaceutical Technology Co., Ltd.
上海帛亦醫(yī)藥科技有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
鉅瀾化工科技(青島)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
鉅瀾化工科技(青島)有限公司
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.